Claims for Patent: 10,004,807

Summary for Patent: 10,004,807

Title:	Pharmaceutical compositions comprising fatty acid esters
Abstract:	The present invention relates to an injectable, pharmaceutical composition comprising a C.sub.1-6 alkyl ester of a C.sub.10-20 fatty acid. In an embodiment, the fatty acid is ethyl oleate, isopropyl oleate, ethyl myristate, or isopropyl myristate. These compositions are useful for the delivery of anti-psychotic drugs.
Inventor(s):	Perry; Jason M. (Waltham, MA), Hickey; Magali B. (Waltham, MA), Remenar; Julius F. (Waltham, MA), Vandiver; Jennifer (Waltham, MA)
Assignee:	ALKERMES PHARMA IRELAND LIMITED (Dublin, IE)
Application Number:	13/801,025
Patent Claims:	1. A pharmaceutical composition consisting of: (a) compound A-7: ##STR00026## (b) an alkyl ester of a fatty acid, wherein the alkyl ester of a fatty acid is isopropyl myristate; (c) polysorbate 20; and (d) an aqueous vehicle selected from the group consisting of sterile water, bacteriostatic water for injection, sterile saline solution, Ringer's solution, dextrose solution, phosphate buffer, citrate buffer, tartrate buffer, and acetate buffer; wherein the composition forms an aqueous, flocculated, injectable suspension. 2. The composition of claim 1, wherein (b) and (c) are present at a ratio that results in flocs comprising component (a) wherein the flocs settle to greater than a predetermined sediment bed height, such that components (a), (b) and (c) can be resuspended for injection. 3. The composition of claim 2, wherein the bed height is comprised of at least a 20 to 160% higher sediment height compared to a non-flocculated composition after 24 hours of undisturbed sitting. 4. The composition of claim 2, wherein the ratio of (b) to (c) is such that the composition can be injected using a 20 or greater gauge needle. 5. The composition of claim 2, wherein the ratio of (b) to (c) is approximately 2.5 to 1, by weight. 6. The composition of claim 2, wherein the ratio of (b) to (c) is approximately 1 to 1, by weight. 7. The composition of claim 2, comprising about 0.2-1 weight percent isopropyl myristate. 8. The composition of claim 2, comprising about 0.05-0.8 weight percent polysorbate 20. 9. The composition of claim 2, wherein the concentration of (a) is approximately 15-35 weight percent. 10. An injectable pharmaceutical composition consisting of: (a) compound A-7: ##STR00027## (b) isopropyl myristate; (c) polysorbate 20; and (d) an aqueous carrier selected from the group consisting of sterile water, bacteriostatic water for injection, sterile saline solution, Ringer's solution, dextrose solution, phosphate buffer, citrate buffer, tartrate buffer, and acetate buffer. 11. The injectable pharmaceutical composition of claim 10 comprising: (a) approximately 15-35 weight percent compound A-7; (b) approximately 0.2-1 weight percent isopropyl myristate; and (c) approximately 0.05-0.8 weight percent polysorbate 20. 12. A pharmaceutical composition consisting of: (a) 20-30 weight percent compound A-7: ##STR00028## (b) 0.2-1 weight percent isopropyl myristate; (c) 0.05-0.8 weight percent polysorbate 20; and (d) an aqueous carrier selected from the group consisting of sterile water, bacteriostatic water for injection, sterile saline solution, Ringer's solution, dextrose solution, phosphate buffer, citrate buffer, tartrate buffer, and acetate buffer. 13. The composition of claim 2, comprising about 0.2-0.5 weight percent isopropyl myristate. 14. The composition of claim 1, wherein the sterile saline solution is a phosphate-buffered saline. 15. The composition of claim 10, wherein the sterile saline solution is a phosphate-buffered saline. 16. The composition of claim 12, wherein the sterile saline solution is a phosphate-buffered saline.

Details for Patent 10,004,807

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2032-03-19